The deal is AstraZeneca#39;s second this month after it agreed last week to buy Amolyt Pharma for $1.05 billion to shore up its rare disease portfolio.
Your email address will not be published. Required fields are marked *
Save my name, email, and website in this browser for the next time I comment.
Leave a Comment